Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Todd A. Hembrough"'
2
Data from ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action
Autor: Mark R. Bray, Carolyn F. Sidor, William E. Fogler, Stacy M. Plum, Todd A. Hembrough, Trisha A. Denny, Richard D. Brokx, Graham C. Fletcher
ENMD-2076 is a novel orally active, small molecule kinase inhibitor with a mechanism of action involving several pathways key to tumor growth and survival: angiogenesis, proliferation, and the cell cycle. ENMD-2076 has selective activity against the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de9a7ae9d78aa981d9140702e0585e01
https://doi.org/10.1158/1535-7163.c.6531383
Zobrazit plný text záznamu
3
ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action
Autor: Mark R. Bray, Todd A. Hembrough, William E. Fogler, Trisha Denny, C. Sidor, Stacy M. Plum, Graham C. Fletcher, Richard Brokx
Publikováno v: Molecular Cancer Therapeutics. 10:126-137
ENMD-2076 is a novel orally active, small molecule kinase inhibitor with a mechanism of action involving several pathways key to tumor growth and survival: angiogenesis, proliferation, and the cell cycle. ENMD-2076 has selective activity against the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40842c6a51148a3d0f5c2259df861789
https://doi.org/10.1158/1535-7163.mct-10-0574
Zobrazit plný text záznamu
4
The hematopoietic-specific β1-tubulin is naturally resistant to 2-Methoxyestradiol and protects patients from drug-induced myelosuppression
Autor: Daniel Escuin, James P. Snyder, Grainne Mcmahon-Tobin, Patricia Burke, Luis J Leandro-García, Yuefang Wang, Todd A. Hembrough, Ana A. Alcaraz, Paraskevi Giannakakou, Theresa LaVallee, Cristina Rodríguez-Antona
Publikováno v: Cell Cycle. 8:3914-3924
Taxanes and other microtubule-targeting drugs (MTDs) represent one of the most effective classes of cancer chemotherapeutics. However, ultimately their utility is limited due to drug-induced myelosuppression. Here we identify 2-Methoxyestradiol (2ME2
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba6d1c7725541c1481ffc22e03e7d10e
https://doi.org/10.4161/cc.8.23.10105
Zobrazit plný text záznamu
5
Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity
Autor: Stacy M. Plum, Todd A. Hembrough, Victor S. Pribluda, Mark S. Williams, Li Zhang, Glenn M. Swartz, Dudley K. Strickland, Bonnie M. Swerdlow, Jose F. Ruiz, Hans J. Hammers
Publikováno v: Blood. 103:3374-3380
Tissue factor pathway inhibitor (TFPI) is the major physiologic inhibitor of the extrinsic coagulation pathway. We have previously shown that TFPI is also a potent inhibitor of endothelial proliferation in vitro and of primary and metastatic tumor gr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11e21e9544843416d65d7993cf319df7
https://doi.org/10.1182/blood-2003-07-2234
Zobrazit plný text záznamu
6
Investigating tumoral and temporal heterogeneity through comprehensive -omics profiling in patients with metastatic triple negative breast cancer
Autor: Christopher Szeto, Rahul Parulkar, AJ Sedgewick, Stephen Charles Benz, Fabiola Cecchi, Todd A. Hembrough, Charles Joseph Vaske, Zack Sanborn, Shahrooz Rabizadeh, Elisabeth Mahen, Kimberly Burton, Patrick Soon-Shiong, Nicole Maria Kuderer, Francis Mark Senecal, Sibel Blau, C. Anthony Blau
Publikováno v: Journal of Clinical Oncology. 35:1093-1093
1093 Background: The “Intensive Trial of OMics in Cancer”-001 (ITOMIC-001; Clinicaltrials.gov ID: NCT01957514) enrolls patients with metastatic triple negative breast cancer (TNBC) who are platinum-naive and scheduled to receive cisplatin. Multip
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::982668321b14429649b7dc26fa13e830
https://doi.org/10.1200/jco.2017.35.15_suppl.1093
Zobrazit plný text záznamu
8
Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism
Autor: Todd A, Hembrough, Glenn M, Swartz, Adonia, Papathanassiu, George P, Vlasuk, William E, Rote, Shawn J, Green, Victor S, Pribluda
Publikováno v: Cancer research. 63(11)
An association between cancer and thrombosis has been recognized for more than a century. However, the manner by which tumor growth is regulated by coagulation in vivo remains unclear. To assess the role of coagulation on tumor growth, in vivo, we te
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ede0bcef0501de4931faf65ff65838b8
https://pubmed.ncbi.nlm.nih.gov/12782609
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje